INSM ARIKAYCE: Full Approval Near-Certain, $26B Priced In

Insmed’s ARIKAYCE is about to get the one thing it has been waiting eight years for: full FDA approval. The supplemental application cleared its biggest hurdle on September 21 when the FDA accepted it under Priority Review with a January 28, 2027 target action date. The Phase 3b ENCORE data behind it is clean. The culture conversion numbers are the best in the history of this disease. And the stock, at $117.83 with a $26.5 billion market cap, has already moved past the approval question entirely.

Here is the thing about this catalyst that most coverage will miss. ARIKAYCE full approval is not the story. The story is whether moving ARIKAYCE from a last-line drug for refractory patients to a frontline drug for newly diagnosed patients actually changes the revenue trajectory of a company whose real growth engine is a different drug entirely.

The Data: Approval Is Not the Risk

ENCORE was the confirmatory trial Insmed owed the FDA after ARIKAYCE won accelerated approval in 2018 under the Limited Population Pathway. The trial randomized 425 patients with a new MAC lung infection, none of whom had received prior antibiotics, to ARIKAYCE plus standard multidrug therapy or placebo plus multidrug therapy.

The results did what Insmed needed. Culture conversion by month 6 hit 87.8% on ARIKAYCE versus 57.0% on placebo, a 30.8 percentage point gap with p less than 0.0001. That held through month 13 at 82.4% versus 55.6%, and durable conversion at month 15 after treatment stopped was 76.2% versus 47.6%. The primary endpoint, change in respiratory symptom score at month 13, also hit: 17.77 points versus 14.66, a 3.11 point difference with p equal to 0.0299.

That primary endpoint p-value is worth sitting with. It is the weakest number in the dataset, and it barely cleared the bar. The fatigue endpoint missed outright, with p equal to 0.29. Insmed got its approval on the back of the culture conversion results, which are genuinely strong and were the original basis for the accelerated approval. The symptom and fatigue data are softer, and that is the crack a cautious FDA could wedge into the label. But the FDA already granted Priority Review, which is a signal that the agency does not see a clinical blocker. The CMC and safety story is well understood after eight years on market. The approval probability sits north of 85%, with the full approval plus frontline expansion at roughly 70%. This is not a coin flip.

The safety data in ENCORE was in line with the known profile, which is to say it is the real constraint on ARIKAYCE. Dysphonia hit 58.7% versus 8.5% on placebo. Bronchospasm was 23% versus 11.8%. The discontinuation rate was 18.3% versus 11.8%. This is a drug that works by being inhaled, and the inhaled route is the source of most of its tolerability baggage. None of this is new, and none of it should stop approval. The full details are on ClinicalTrials.gov.

The Real Question: Does Frontline Move the Needle?

ARIKAYCE did $433.8 million in 2025 revenue, up 19% year over year, and Insmed is guiding to $450 million to $470 million in 2026. That is a drug growing in the high single to low double digits while still restricted to refractory patients who failed at least six months of standard therapy.

The frontline expansion changes the math. MAC lung disease is a progressive infection where standard two-drug therapy produces suboptimal culture conversion and frequent relapse. The ENCORE data showed that adding ARIKAYCE from day one nearly doubles durable culture conversion. The addressable population for frontline is meaningfully larger than the refractory niche the drug has been stuck in since 2018. If the label expands to newly diagnosed and recurrent patients, ARIKAYCE’s peak sales move from the roughly $500 million it is tracking toward today into the low single-digit billions over the next several years.

But here is the problem for anyone treating this as a pure ARIKAYCE catalyst. Insmed’s market cap is $26.5 billion, and it is being valued on brensocatib, not ARIKAYCE. Brensocatib, branded BRINSUPRI, launched for non-cystic fibrosis bronchiectasis and is guiding to at least $1 billion in 2026, with management raising the range to $1.25 billion to $1.40 billion after the Q2 beat. Insmed now says its three lead programs have combined peak sales potential over $14 billion, with BRINSUPRI alone guided above $7 billion. ARIKAYCE full approval adds to that stack, but it is the smaller, slower leg.

Valuation: The Approval Is Already in the Price

The cleanest way to see this is through the analyst tape. The average price target is near $200, with Morgan Stanley at $218 and a wave of post-Q2 hikes from Mizuho, Truist, UBS, Wells Fargo, and Jefferies. Every one of those targets is built on BRINSUPRI’s launch trajectory and its path to $7 billion in peak sales. ARIKAYCE full approval moves the needle only at the margin.

The stock trades at roughly 13 times 2026 revenue guidance of about $2 billion when you add ARIKAYCE’s $450 million to $470 million to BRINSUPRI’s $1.25 billion to $1.40 billion. That is a premium multiple, and it is justified by the BRINSUPRI growth rate, which saw U.S. revenue go from zero to $308.6 million in a single quarter. ARIKAYCE full approval does not change that multiple. It removes a small amount of tail risk and adds a mid-single-digit percentage to the revenue base.

For comps, Insmed is best understood against the rare pulmonary disease names covered in prior sector coverage rather than against broad biotech. The sector roundup is here, and the pattern that matters is the same one seen in the Jazz Ziihera label expansion: when a drug’s label expands but the market cap is already being driven by a bigger franchise, the label expansion is a confirmation event, not a re-rating event.

Risks

The concrete risk here is not approval. It is the label wording. If the FDA grants full approval but writes a narrow frontline indication that still excludes a meaningful share of newly diagnosed patients, the expansion is worth less than the bulls are modeling. The FDA’s caution around the soft symptom endpoint and the missed fatigue endpoint is the specific reason the label could come in narrower than hoped. That would not tank the stock, but it would trim the ARIKAYCE peak sales contribution.

The second risk is the one that actually moves Insmed’s valuation: BRINSUPRI. The stock is priced for a $7 billion plus peak sales trajectory, and any stumble in the launch, a reimbursement headwind, or a slower-than-expected ramp into the COPD and asthma expansion populations would hit the stock far harder than anything ARIKAYCE does in January. ARIKAYCE full approval is correlated with the good story, not with the risk.

Verdict

ARIKAYCE full approval on January 28, 2027 is a near-certainty, and the frontline expansion is likely to follow. The ENCORE culture conversion data is the best ever produced in MAC lung disease, and the FDA’s Priority Review grant is the tell that the agency is not looking for a reason to say no.

But do not buy Insmed for the ARIKAYCE PDUFA. The market has already priced full approval and most of the frontline upside into a $26.5 billion market cap that is fundamentally a brensocatib story. The ARIKAYCE catalyst is a confirmation, not a re-rating.

Hold Insmed here, do not add on the PDUFA. If you are building a position, the entry that matters is tied to BRINSUPRI’s quarterly launch trajectory, not to the January approval. ARIKAYCE full approval will generate a headline and maybe a one-day pop, but the durable move in this stock is already being driven by a different drug, and it has been for a year.